Genentech will pay Array BioPharma $28 million as part of a deal to jointly develop the companies’ small-molecule inhibitors of Checkpoint kinase 1 (ChK-1), a protein implicated in cancer cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results